Achilles Therapeutics is a clinical-stage biopharmaceutical company developing personalized T cell therapies for solid tumors. The core concept is that most cancers carry mutations present in every tumor cell from the start of tumor development — called clonal neoantigens — and Achilles builds therapies that target those specific mutations. Because these targets appear on all tumor cells but not on healthy tissue, Achilles argues the approach can be both more effective and safer than existing cancer immunotherapies. The lead product candidate, ATL001, is a clonal neoantigen-reactive T cell (cNeT) therapy in Phase I/IIa trials for non-small cell lung cancer (NSCLC) and metastatic melanoma. Each therapy is fully personalized: tumor and blood samples are collected from the patient, sequenced, and analyzed by PELEUS — Achilles' AI-driven bioinformatics platform — to identify and rank clonal neoantigens. VELOS, its manufacturing process, then uses those targets to selectively expand T cells that recognize the patient's specific tumor mutations, producing a tailored cNeT product infused back into the patient over an eight-to-nine week cycle. Achilles has exclusive commercial access to the TRACERx study dataset, which it uses to train PELEUS. The company also runs a hospital network to collect tumor samples across cancer types, expanding the platform's capabilities. Achilles has no approved products and no revenue, funding operations through equity raises. If commercialized, the business model would involve selling a per-patient therapy to specialized cancer centers, with economics depending heavily on manufacturing cost reduction, clinical efficacy, and payor reimbursement.